The importance of immunoregulatory T cells has become increasingly apparent. Both CD4+CD25+ T cells and CD1d-restricted NKT cells have been reported to down-regulate tumor immunity in mouse tumor models. However, the relative roles of both T cell populations have rarely been clearly distinguished in the same tumor models. In addition, CD1d-restricted NKT cells have been reported to play a critical role not only in the down-regulation of tumor immunity but also in the promotion of the immunity. However, the explanation for these apparently opposite roles in different tumor models remains unclear. We show that in four mouse tumor models in which CD1d-restricted NKT cells play a role in suppression of tumor immunity, depletion of CD4+CD25+ T cells did not induce enhancement of immunosurveillance. Surprisingly, among the two subpopulations of CD1d-restricted NKT cells, Vα14Jα18+ (type I) and Vα14Jα18− (type II) NKT cells, type I NKT cells were not necessary for the immune suppression. These unexpected results may now resolve the paradox in the role of CD1d-restricted NKT cells in the regulation of tumor immunity, in that type II NKT cells may be sufficient for negative regulation, whereas protection has been found to be mediated by α-galactosylceramide–responsive type I NKT cells.
Skip Nav Destination
Article navigation
19 December 2005
Brief Definitive Report|
December 19 2005
A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance
Masaki Terabe,
Masaki Terabe
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Jeremy Swann,
Jeremy Swann
2Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Search for other works by this author on:
Elena Ambrosino,
Elena Ambrosino
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Pratima Sinha,
Pratima Sinha
3Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, MD 21250
Search for other works by this author on:
Shun Takaku,
Shun Takaku
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Yoshihiro Hayakawa,
Yoshihiro Hayakawa
2Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Search for other works by this author on:
Dale I. Godfrey,
Dale I. Godfrey
4Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria 3010, Australia
Search for other works by this author on:
Suzanne Ostrand-Rosenberg,
Suzanne Ostrand-Rosenberg
3Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, MD 21250
Search for other works by this author on:
Mark J. Smyth,
Mark J. Smyth
2Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Search for other works by this author on:
Jay A. Berzofsky
Jay A. Berzofsky
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Masaki Terabe
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Jeremy Swann
2Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Elena Ambrosino
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Pratima Sinha
3Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, MD 21250
Shun Takaku
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Yoshihiro Hayakawa
2Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Dale I. Godfrey
4Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria 3010, Australia
Suzanne Ostrand-Rosenberg
3Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, MD 21250
Mark J. Smyth
2Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Jay A. Berzofsky
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
CORRESPONDENCE Masaki Terabe: [email protected] OR Jay A. Berzofsky: [email protected]
M. Terabe and J. Swann contributed equally to this work.
Received:
July 11 2005
Accepted:
November 10 2005
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2005
J Exp Med (2005) 202 (12): 1627–1633.
Article history
Received:
July 11 2005
Accepted:
November 10 2005
Citation
Masaki Terabe, Jeremy Swann, Elena Ambrosino, Pratima Sinha, Shun Takaku, Yoshihiro Hayakawa, Dale I. Godfrey, Suzanne Ostrand-Rosenberg, Mark J. Smyth, Jay A. Berzofsky; A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance . J Exp Med 19 December 2005; 202 (12): 1627–1633. doi: https://doi.org/10.1084/jem.20051381
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement